Nevrargenics is a drug discovery and development company working towards understanding, treating and reversing neurodegenerative diseases.
Our interests are widely across neurodegenerative diseases through a novel dual-acting small molecule, which may be valuable in treating a number of closely linked diseases, such as ALS, FTD and Alzheimer’s disease.
With novel intellectual property in this area, Nevrargenics is planning to advance its lead drug candidates through the preclinical stages and into clinical trials.
Nevrargenics’ strategy involves targeting major unmet needs by developing global blockbusters for Alzheimer’s, Parkinson’s and other neurodegenerative and related diseases, some of which have orphan drug status (e.g. ALS and FTD) as an indication and, with the longer term view of.
Nevrargenics is also actively looking at a wider scientific understanding of the diseases, their causes and links between the different types of clearly related diseases.
Our novel drugs are not only being developed to try and improve the quality of life of neurodegenerative disease suffers, but are also being used as biological probes for developing a deeper understanding of the causation of these diseases.
According to a report from the World Health Organization (WHO), neurological disorders affect up to one billion people worldwide. Neurological disorders include diseases caused by degeneration of the nerves, such as Alzheimer’s, Multiple Sclerosis, ALS and Parkinson’s, that cause a huge burden to society and have very limited treatment options.
An estimated 6.8 million people die every year as a result of neurological disorders. In Europe, the economic cost of neurological diseases is estimated at 140 billion euros.
Innovative and proprietary medicines for serious medical needs.
These diseases have a tragic impact upon patients and impact the lives of carers and society as a whole. Together with novel therapies, there is profound need for a deeper understanding of the underlying causes of neurodegenerative diseases.
We neither fully understand the links between these diseases, nor their root cause(s) and, even worse, suffer from a complete lack of effective treatments for all of them.
Our strategy is to employ new, dual-acting, retinoic acid receptor modulators (RAR-M) as lead potential drugs for developing rational and effective new treatment regimes and meeting the major neurodegenerative therapeutic needs.
In addition, we will use our lead candidates to investigate and characterise their impact on the underlying mechanisms and use this knowledge to target the wider range of neurodegenerative diseases.
We are currently in discussions with potential partners for the development journey ahead, to progress our novel small molecules for the benefit of so many patients around the world as well as their carers.
If you are interested in collaborating please contact us